The Moyamoya Disease pathophysiology overview
Moyamoya disease is a rare, progressive cerebrovascular disorder characterized by the narrowing and eventual occlusion of the arteries at the base of the brain, specifically the internal carotid arteries and their main branches. The term “moyamoya,” which means “puff of smoke” in Japanese, describes the appearance of the abnormal collateral vessels that develop as a compensatory response to arterial blockage. Understanding its pathophysiology involves exploring the underlying vascular changes, molecular mechanisms, and the body’s attempt to maintain cerebral perfusion in the face of arterial stenosis.
The initial hallmark of moyamoya disease is the progressive stenosis or occlusion of the distal internal carotid arteries as well as the proximal segments of the anterior and middle cerebral arteries. This narrowing reduces blood flow to critical areas of the brain, leading to ischemic symptoms like transient ischemic attacks, strokes, or neurological deficits. The underlying cause of this arterial narrowing remains largely idiopathic, but genetic and environmental factors are believed to contribute.
As the primary arteries become constricted, the brain responds by forming a network of tiny, fragile collateral vessels in an attempt to bypass the blockage. These vessels originate from the basal lenticulostriate arteries, striate arteries, and other smaller arteries around the circle of Willis. They proliferate rapidly, creating a tangled, web-like structure that appears as a “puff of smoke” on cerebral angiography, which is the hallmark radiological feature of the disease.
At the molecular level, several hypotheses suggest mechanisms driving the characteristic vascular changes. One theory involves abnormal proliferation of smooth muscle cells within the arterial walls, leading to intimal hyperplasia and thickening, which narrows the vessel lumen. This hyperplastic process may be driven by genetic mutations affecting signaling pathways responsible for vascular growth and remodeling. For instance, mutations in the RNF213 gene have been strongly associated with moyamoya disease, particularly in East Asian populations, implying a genetic predisposition to abnormal vascular proliferation and remodeling.
Additionally, inflammation and oxidative stress are believed to play roles in the disease’s progression. Chronic inflammation could contribute to endothelial dysfunction, promoting intimal hyperplasia and vessel wall thickening. The fragile collateral vessels, although vital for maintaining cerebral perfusion, are structurally weak and prone to rupture, increasing the risk of hemorrhagic strokes.
The hemodynamic consequences of these vascular changes are significant. As the primary arteries narrow, cerebral blood flow becomes compromised, especially during episodes of systemic hypoperfusion or increased metabolic demand. The formation of collateral vessels attempts to compensate, but their fragility and inefficient blood flow often fail to fully prevent ischemic injury. The balance between ischemia and hemorrhage risk is delicate, and the disease’s progression varies among individuals.
In summary, moyamoya disease involves a complex interplay of genetic predisposition, abnormal vascular proliferation, and collateral formation in response to progressive arterial stenosis. These changes lead to chronic cerebral hypoperfusion and the formation of fragile collateral networks, which can cause a spectrum of neurological symptoms, from ischemic strokes to hemorrhages. Ongoing research continues to uncover the molecular and genetic underpinnings of the disease, offering hope for targeted therapies in the future.